HS-10374 vs Nomelcitinib (D-2570)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

HS-10374

Developed by Hansoh Pharmaceutical Group

Phase 3 in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Nomelcitinib (D-2570)

Developed by InventisBio

Phase 3 in PsoriasisSmall molecule (oral TYK2 JH2 pseudokinase-domain inhibitor)
Partial signal

NCT06278350 · Phase 2 · completed

The study randomized 161 participants with moderate to severe plaque psoriasis to three D-2570 dose groups or placebo, with participants, care providers and investigators masked. The primary endpoint, PASI 75 at week 12, was met in all three dose groups versus placebo (at least 85% vs 12.5%, p<0.001), per the sponsor's release and the peer-reviewed publication. The trial is mid-sized and 12 weeks long, so durability and safety beyond week 12 are not established.

Next expected readout: July 2027 · NCT07326813 (registry estimate)

Reported efficacy

Percentage of subjects with at least 75% improvement in PASI (Day 1-Day 85): Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) (met)

Result source: NCT06278350

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHS-10374Nomelcitinib (D-2570)
PASI 75—Trial running · NCT06672393—Trial running · NCT07130604
PASI 90—Trial running · NCT06672393—Trial running · NCT07130604
PASI 100—Trial running · NCT06672393—Trial running · NCT07130604
sPGA 0/1—Trial running · NCT06672393—Trial running · NCT07130604
DLQI, change—Trial running · NCT06672393—Trial running · NCT07130604

PASI 75

HS-10374
—Trial running · NCT06672393
Nomelcitinib (D-2570)
—Trial running · NCT07130604

PASI 90

HS-10374
—Trial running · NCT06672393
Nomelcitinib (D-2570)
—Trial running · NCT07130604

PASI 100

HS-10374
—Trial running · NCT06672393
Nomelcitinib (D-2570)
—Trial running · NCT07130604

sPGA 0/1

HS-10374
—Trial running · NCT06672393
Nomelcitinib (D-2570)
—Trial running · NCT07130604

DLQI, change

HS-10374
—Trial running · NCT06672393
Nomelcitinib (D-2570)
—Trial running · NCT07130604
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HS-10374: no structured comparison results are available for Psoriasis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Nomelcitinib (D-2570)
Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) NCT06278350 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-10374's landscape · Nomelcitinib (D-2570)'s landscape